China Point-Of-Care Testing (POCT) Market Research Report 2022

China Point-Of-Care Testing (POCT) Market Research Report 2022

Market Analysis and Insights: China Point-of-Care Testing (POCT) Market

Due to the COVID-19 pandemic, the China Point-of-Care Testing (POCT) market size is estimated to be worth US$ 2341 million in 2022 and is forecast to a readjusted size of US$ 4959 million by 2028 with a CAGR of 13.33% during the review period. Fully considering the economic change by this health crisis, Blood Glucose Testing accounting for 43.75% of the Point-of-Care Testing (POCT) China market in 2021, is projected to value US$ 1797 million by 2028, growing at a revised 10.8% CAGR in the forecast period.

In China, the key manufacturers of Point-of-Care Testing (POCT) include Roche, Abbott, LifeScan, Siemens Healthineers, Danaher, Ascensia, Bio-Rad Laboratories, BioMerieux, and ARKRAY, etc. In 2021, the top five players have a share approximately XX% in terms of revenue.

China Point-of-Care Testing (POCT) Scope and Segment

Point-of-Care Testing (POCT) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the China Point-of-Care Testing (POCT) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type, and by Application for the period 2017-2028.

Segment by Type

Blood Glucose Testing

Infectious Diseases Testing

Cardiac Markers Testing

Coagulation Testing

Pregnancy and Fertility Testing

Blood Gas/Electrolytes Testing

Urinalysis Testing

Other

Segment by Application

Clinics

Hospitals

Laboratory

Others

By Company

Roche

Abbott

LifeScan

Siemens Healthineers

Danaher

Ascensia

BioMerieux

ARKRAY

Sinocare

Wondfo

Yuwell

Runbio

KHB

Wuhan Easy Diagnosis

J.H.Bio-Tec

Getein Biotech

ReLIA

BIOUHAN

Beijing Wantai BioPharm

Hotgen

Intec PRODUCT

Shenzhen YHLO

Kang Hua